TransMedics Group, Inc. reported an insider ownership update for Nicholas Corcoran, identified in the filing remarks as the company’s Senior Vice President of Supply Chain and Operations. The Form 4 was filed July 14, 2026, and lists a transaction/report date of July 10, 2026, involving TransMedics common stock. The filing indicates that Corcoran’s reported beneficial ownership includes 11,727 restricted stock units, or RSUs. Each RSU represents a contingent right to receive one share of TransMedics common stock, meaning the units are equity compensation that may convert into shares subject to the terms of the award. The document excerpt does not show an open-market purchase or sale price for these RSUs, nor does it provide a transaction code in the available text. The filing also references a stock option award with a monthly vesting schedule. The option vests at a rate of 2.0833% of the total shares subject to the option each month after April 10, 2026, and is scheduled to become fully vested on April 10, 2030, assuming Corcoran continues to provide service through the vesting period. The excerpt does not specify the number of shares underlying the option or its exercise price. Overall, the filing reports an insider equity-compensation ownership update rather than a clearly described market transaction. For investors, the key point is that a senior operations executive holds equity-linked compensation tied to TransMedics common stock, including 11,727 RSUs and an option that vests over four years, aligning part of the executive’s compensation with the company’s share performance and continued service.